Patents Assigned to Savient Pharmaceuticals, Inc.
  • Variant Forms of Urate Oxidase and Use Thereof
    Publication number: 20130330803
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 12, 2013
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant forms of urate oxidase and use thereof
    Patent number: 8541205
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: September 24, 2013
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant form of urate oxidase and use thereof
    Patent number: 8465735
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: June 18, 2013
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant Form of Urate Oxidase and Use Thereof
    Publication number: 20130084273
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: September 20, 2012
    Publication date: April 4, 2013
    Applicant: Savient Pharmaceuticals, Inc.
    Inventor: Savient Pharmaceuticals, Inc.
  • Methods for Assessing Tophus Response During Urate Lowering Therapy in Treatment Tophaceous Gout
    Publication number: 20120323107
    Abstract: Systems and methods for assessment of the reduction of tophus burden with effective urate-lowering therapy were developed. The first application of computer-assisted methods for accessing tophus response included standardized digital photography, computer assisted measurement and analysis of tophi by an independent reader and blinded central reader paradigm. The ability of the method for computer-assisted analysis of digital photographs to quantify reduction in tophus size demonstrates its feasibility as a urate-lowering therapy monitoring tool in the treatment of tophaceous gout.
    Type: Application
    Filed: June 25, 2010
    Publication date: December 20, 2012
    Applicants: Corelab Partners, Inc., Savient Pharmaceuticals, Inc.
    Inventors: Allan Maroli, Michelle Alton, Royce W. Waltrip, Claudia Rehrig, Bill Huang, Zebulun Horowitz, Robert Ford
  • Variant Forms of Urate Oxidase and Use Thereof
    Publication number: 20120309085
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Application
    Filed: May 1, 2012
    Publication date: December 6, 2012
    Applicant: SAVIENT PHARMACEUTICALS, INC.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant form of urate oxidase and use thereof
    Patent number: 8293228
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: October 23, 2012
    Assignee: Savient Pharmaceuticals Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • VARIANT FORM OF URATE OXIDASE AND USE THEREOF
    Publication number: 20120225046
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: April 20, 2012
    Publication date: September 6, 2012
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant forms of urate oxidase and use thereof
    Patent number: 8188224
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: May 29, 2012
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant form of urate oxidase and use thereof
    Patent number: 8178334
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: May 15, 2012
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
    Patent number: 8148123
    Abstract: A method for lowering elevated uric acid levels in patients is disclosed and consists of administering to the patients an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: April 3, 2012
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz, Claudia D. Rehrig, William Huang, Michael Hershfield
  • VARIANT FORM OF URATE OXIDASE AND USE THEREOF
    Publication number: 20120070876
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 22, 2012
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Use of oxandrolone in the treatment of burns and other wounds
    Patent number: 8053425
    Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: November 8, 2011
    Assignee: Savient Pharmaceuticals, Inc.
    Inventor: Don Fishbein
  • Variant form of urate oxidase and use thereof
    Patent number: 8034594
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: October 11, 2011
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Use of oxandrolone in the treatment of burns and other wounds
    Patent number: 8026274
    Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: September 27, 2011
    Assignee: Savient Pharmaceuticals, Inc.
    Inventor: Don Fishbein
  • VARIANT FORM OF URATE OXIDASE AND USE THEREOF
    Publication number: 20110217755
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: May 13, 2011
    Publication date: September 8, 2011
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant form of urate oxidase and use thereof
    Patent number: 7964381
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: June 21, 2011
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • VARIANT FORM OF URATE OXIDASE AND USE THEREOF
    Publication number: 20110104751
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: September 10, 2010
    Publication date: May 5, 2011
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant form of urate oxidase and use thereof
    Patent number: 7811800
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: October 12, 2010
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Variant Forms of Urate Oxidase and Use Thereof
    Publication number: 20090169534
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Application
    Filed: April 11, 2006
    Publication date: July 2, 2009
    Applicant: SAVIENT PHARMACEUTICALS, INC.
    Inventors: Jacob Hartman, Simona Mendelovitz